Adaptimmune creates engineered T‑cell receptor (TCR) therapies that enable patient T cells to recognize peptide‑HLA complexes derived from intracellular tumor proteins, expanding treatment options for solid‑tumor cancers. Its platform combines target discovery, affinity‑enhanced TCR design, and a pre‑clinical safety screen to produce high‑potency, highly specific candidates for oncology developers and clinicians.

Gilead Sciences discovers, develops, and delivers innovative therapeutics for serious viral, oncologic, and inflammatory diseases, maintaining a portfolio of over 25 approved medicines and a pipeline of 47 clinical‑stage programs. The company expands global access through licensing, partnerships, and philanthropy, reaching patients in more than 120 countries while integrating ESG initiatives to support sustainable health outcomes.